ClinicalTrials.Veeva

Menu

Effect of Memantine on Cognitive Impairment in Patients With Epilepsy

A

Assiut University

Status and phase

Completed
Phase 1

Conditions

Epilepsy

Treatments

Drug: Memantine Hydrochloride
Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT04417543
Memantine in epilepsy

Details and patient eligibility

About

Evaluate the efficacy of memantine on improving the cognitive impairment in patient with epilepsy

Full description

Epilepsy is a complex disorder, which involves much more than seizures, encompassing a range of associated comorbid health conditions that can have significant health and quality-of-life implications. Of these comorbidities, cognitive impairment is one of the most common and distressing aspects of epilepsy.

Excito-toxicity, mediated by glutamate acting on N-methyl-D-aspartate (NMDA) receptors in the hippocampus, can cause memory dysfunction in epilepsy .

Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor . It also has antioxidant property and increases production of brain derived neurotropic factor (BDNF)

Enrollment

100 patients

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with idiopathic epilepsy.
  • Normal brain imaging (CT brain).
  • Patients on anti epileptic drugs more than 6 months.
  • No more than two fits per month.
  • Score of Mini mental state examination (10-24), mild and moderate cognitive impairment.
  • No other medical disorders.

Exclusion criteria

  • Progressive neurological diseases.
  • Abnormal brain imaging (CT brain).
  • More than two fits per month.
  • Patients with severe cognitive impairment, score of MMSE less than10.
  • Patients with severe medical disorders

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

100 participants in 2 patient groups, including a placebo group

Memantine hydrochloride group
Active Comparator group
Description:
included 50 patients who received memantine
Treatment:
Drug: Memantine Hydrochloride
Placebo group
Placebo Comparator group
Description:
included 50 patients who received placebo
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems